BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19487592)

  • 1. Impact of percutaneous device implantation for closure of patent foramen ovale on valve insufficiencies.
    Wöhrle J; Kochs M; Spiess J; Nusser T; Hombach V; Merkle N
    Circulation; 2009 Jun; 119(23):3002-8. PubMed ID: 19487592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and brain magnetic resonance imaging follow-up after percutaneous closure of patent foramen ovale in patients with cryptogenic stroke.
    Vigna C; Inchingolo V; Giannatempo G; Pacilli MA; Di Viesti P; Fusilli S; Amico CM; Santoro T; Lanna P; Fanelli R; Simone P; Loperfido F
    Am J Cardiol; 2008 Apr; 101(7):1051-5. PubMed ID: 18359330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Percutaneous closure of patent foramen ovale in young patients with cryptogenic stroke: long-term follow-up].
    Mazuelos F; Suárez de Lezo J; Pan M; Mesa D; Delgado M; Ruiz M; Ojeda S; Esteban F
    Rev Esp Cardiol; 2008 Jun; 61(6):640-3. PubMed ID: 18570787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
    Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urgent transcatheter closure of patent foramen ovale followed by elective right-sided valve surgery for decompensated carcinoid heart disease.
    Hayashi Y; McGaw DJ; Goldstein J
    Heart Lung Circ; 2008 Jun; 17(3):259-61. PubMed ID: 17416551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure.
    Ruiz CE; Kipshidze N; Chiam PT; Gogorishvili I
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):921-6. PubMed ID: 18412251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events.
    Balbi M; Casalino L; Gnecco G; Bezante GP; Pongiglione G; Marasini M; Del Sette M; Barsotti A
    Am Heart J; 2008 Aug; 156(2):356-60. PubMed ID: 18657668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial fibrillation following device closure of patent foramen ovale.
    Burow A; Schwerzmann M; Wallmann D; Tanner H; Sakata T; Windecker S; Meier B; Delacrétaz E
    Cardiology; 2008; 111(1):47-50. PubMed ID: 18239392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low cerebrovascular event rate in subjects with patent foramen ovale and different clinical presentations: results from a prospective non randomized study on a population including patients with and without patent foramen ovale closure.
    Faggiano P; Frattini S; Piovesana P; Lorusso R; Chiari E; Scolari F; Padovani A; Cas LD
    Int J Cardiol; 2012 Apr; 156(1):47-52. PubMed ID: 21112103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder.
    Kutty S; Brown K; Asnes JD; Rhodes JF; Latson LA
    Am J Cardiol; 2008 May; 101(10):1487-92. PubMed ID: 18471463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of aortic valve regurgitation and outcome after percutaneous closure of atrial septal defects and patent foramen ovale.
    Schoen SP; Boscheri A; Lange SA; Braun MU; Fuhrmann J; Kappert U; Strasser RH
    Heart; 2008 Jul; 94(7):844-7. PubMed ID: 18070946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous closure of patent foramen ovale and valvular function -- effect of the amplatzer occluder.
    Krasniqi N; Roth J; Siegrist PT; Toggweiler S; Gruner C; Greutmann M; Tanner FC; Lüscher TF; Corti R
    J Invasive Cardiol; 2012 Jun; 24(6):274-7. PubMed ID: 22684381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of contemporary devices used for transcatheter patent foramen ovale closure.
    Spies C; Reissmann U; Timmermanns I; Schräder R
    J Invasive Cardiol; 2008 Sep; 20(9):442-7. PubMed ID: 18762672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of atrial fibrillation after transcatheter closure of patent foramen ovale in patients with or without cryptogenic stroke.
    Bronzetti G; D'Angelo C; Donti A; Salomone L; Giardini A; Maria Picchio F; Boriani G
    Int J Cardiol; 2011 Jan; 146(1):17-21. PubMed ID: 19487038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
    Ussia GP; Cammalleri V; Mulè M; Scarabelli M; Barbanti M; Scardaci F; Mangiafico S; Immè S; Capodanno D; Tamburino C
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):607-14. PubMed ID: 19360875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke.
    Thanopoulos BV; Dardas PD; Karanasios E; Mezilis N
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):741-6. PubMed ID: 17039525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, timing, and predictive factors of new-onset migraine headache attack after transcatheter closure of atrial septal defect or patent foramen ovale.
    Rodés-Cabau J; Mineau S; Marrero A; Houde C; Mackey A; Côté JM; Chetaille P; Delisle G; Bertrand OF; Rivest D
    Am J Cardiol; 2008 Mar; 101(5):688-92. PubMed ID: 18308022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous closure of patent foramen ovale and atrial septal defect in adults: the impact of clinical variables and hospital procedure volume on in-hospital adverse events.
    Opotowsky AR; Landzberg MJ; Kimmel SE; Webb GD
    Am Heart J; 2009 May; 157(5):867-74. PubMed ID: 19376313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease.
    Mansencal N; Mitry E; Pillière R; Lepère C; Gérardin B; Petit J; Gandjbakhch I; Rougier P; Dubourg O
    Am J Cardiol; 2008 Apr; 101(7):1035-8. PubMed ID: 18359327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder.
    Silvestry FE; Naseer N; Wiegers SE; Hirshfeld JW; Herrmann HC
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):383-7. PubMed ID: 18288733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.